Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients.

Castro E, Olmos D, Garcia A, Cruz JJ, González-Sarmiento R.

Clin Transl Oncol. 2014 Feb;16(2):158-65. doi: 10.1007/s12094-013-1055-8. Epub 2013 Jun 6.

PMID:
23740134
2.

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Chen X, Sun H, Ren S, Kim Curran V, Zhang L, Zhou S, Zhang J, Zhou C.

Clin Transl Oncol. 2012 Mar;14(3):207-13.

PMID:
22374424
3.

Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk.

El-Zein R, Monroy CM, Etzel CJ, Cortes AC, Xing Y, Collier AL, Strom SS.

Cancer. 2009 Apr 15;115(8):1651-9. doi: 10.1002/cncr.24205.

4.

Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.

Yao CY, Huang XE, Li C, Shen HB, Shi MQ, Feng JF, Pan LX, Tang JH.

Asian Pac J Cancer Prev. 2009;10(5):859-64.

5.

Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) polymorphisms in familial and sporadic breast cancer predisposition and survival: an Indian report.

Syamala VS, Syamala V, Sreedharan H, Raveendran PB, Kuttan R, Ankathil R.

Pathol Oncol Res. 2009 Sep;15(3):389-97. doi: 10.1007/s12253-008-9135-8. Epub .

PMID:
19051060
6.

Polymorphisms of the DNA repair genes XPD (Lys751Gln) and XRCC1 (Arg399Gln and Arg194Trp): relationship to breast cancer risk and familial predisposition to breast cancer.

Brewster AM, Jorgensen TJ, Ruczinski I, Huang HY, Hoffman S, Thuita L, Newschaffer C, Lunn RM, Bell D, Helzlsouer KJ.

Breast Cancer Res Treat. 2006 Jan;95(1):73-80. Epub 2005 Dec 1.

PMID:
16319991
7.

The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens.

Artac M, Bozcuk H, Pehlivan S, Akcan S, Pehlivan M, Sever T, Ozdogan M, Savas B.

J Cancer Res Clin Oncol. 2010 Jun;136(6):803-9. doi: 10.1007/s00432-009-0720-3. Epub 2009 Nov 12.

PMID:
19908066
8.

Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain.

López-Cima MF, González-Arriaga P, García-Castro L, Pascual T, Marrón MG, Puente XS, Tardón A.

BMC Cancer. 2007 Aug 16;7:162.

9.

DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.

Kang S, Sun HY, Zhou RM, Wang N, Hu P, Li Y.

Asian Pac J Cancer Prev. 2013;14(2):941-6.

10.

Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.

Wu W, Li H, Wang H, Zhao X, Gao Z, Qiao R, Zhang W, Qian J, Wang J, Chen H, Wei Q, Han B, Lu D.

PLoS One. 2012;7(3):e33200. doi: 10.1371/journal.pone.0033200. Epub 2012 Mar 29.

11.
12.

Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India.

Sreeja L, Syamala VS, Syamala V, Hariharan S, Raveendran PB, Vijayalekshmi RV, Madhavan J, Ankathil R.

J Cancer Res Clin Oncol. 2008 Jun;134(6):645-52. Epub 2007 Oct 19.

PMID:
17952468
13.

DNA repair genes polymorphism and lung cancer risk with the emphasis to sex differences.

Letkova L, Matakova T, Musak L, Sarlinova M, Krutakova M, Slovakova P, Kavcova E, Jakusova V, Janickova M, Drgova A, Berzinec P, Halasova E.

Mol Biol Rep. 2013 Sep;40(9):5261-73. doi: 10.1007/s11033-013-2626-z. Epub 2013 May 15.

PMID:
23673479
14.

Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.

Bewick MA, Conlon MS, Lafrenie RM.

J Clin Oncol. 2006 Dec 20;24(36):5645-51. Epub 2006 Nov 20.

15.

Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.

Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, Selvaggi G, Gregori D, DeMarchi M, Scagliotti GV.

Clin Cancer Res. 2007 May 15;13(10):2876-81.

16.

[Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].

Xu C, Wang X, Zhang Y, Li L.

Zhongguo Fei Ai Za Zhi. 2011 Dec;14(12):912-7. doi: 10.3779/j.issn.1009-3419.2011.12.03. Chinese.

17.

Implication of polymorphisms in DNA repair genes in prognosis of hepatocellular carcinoma.

Yue AM, Xie ZB, Guo SP, Wei QD, Yang XW.

Asian Pac J Cancer Prev. 2013;14(1):355-8.

18.

MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.

Tengström M, Mannermaa A, Kosma VM, Soini Y, Hirvonen A, Kataja V.

Acta Oncol. 2014 Jun;53(6):769-75. doi: 10.3109/0284186X.2014.892210. Epub 2014 Apr 10.

PMID:
24716840
19.

Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.

Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, Zhong R, Xu Y, Wu J, Yu D, Wu T, Zhang X, Nie S, Miao X, Lin D.

Lung Cancer. 2011 Jul;73(1):110-5. doi: 10.1016/j.lungcan.2010.11.004. Epub 2010 Dec 3.

PMID:
21129812
20.

DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.

Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Cespedes M.

J Clin Oncol. 2006 Sep 10;24(26):4333-9. Epub 2006 Aug 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk